The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...
Every cycle has that one moment that splits winners from watchers. That’s the moment a project stops being “one to monitor” and becomes the one people wish ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The long IPO winter is finally coming to an end. And today, it’s a new ...
Kraken’s pending IPO and the wave of crypto companies seeking public listings may help the industry attract more TradFi capital. A potential initial public offering (IPO) next year by cryptocurrency ...
As the global business community converges at Davos, we are seeing powerful catalysts driving M&A and capital markets activity. The foundational drivers that accelerated business activity in the ...
Renaissance IPO ETF (IPO) is rated a buy, anticipating a surge in major IPOs through 2026 to fuel renewed investor interest. IPO’s portfolio is heavily growth-oriented, with 94% SMID-cap exposure and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results